- Home
- INCY vs BAP Comparison
INCY vs BAP Comparison
Compare INCY & BAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- BAP
- Stock Information
- Founded
- INCY 1991
- BAP 1889
- Country
- INCY United States
- BAP Peru
- Employees
- INCY N/A
- BAP N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- BAP Major Banks
- Sector
- INCY Health Care
- BAP Finance
- Exchange
- INCY Nasdaq
- BAP Nasdaq
- Market Cap
- INCY 13.4B
- BAP 14.5B
- IPO Year
- INCY 1993
- BAP 1995
- Fundamental
- Price
- INCY $68.07
- BAP $181.17
- Analyst Decision
- INCY Buy
- BAP Hold
- Analyst Count
- INCY 19
- BAP 3
- Target Price
- INCY $74.38
- BAP $195.67
- AVG Volume (30 Days)
- INCY 1.8M
- BAP 283.5K
- Earning Date
- INCY 04-29-2025
- BAP 02-10-2025
- Dividend Yield
- INCY N/A
- BAP 6.77%
- EPS Growth
- INCY N/A
- BAP 13.11
- EPS
- INCY 0.15
- BAP 18.32
- Revenue
- INCY $4,241,216,999.00
- BAP $4,825,226,157.00
- Revenue This Year
- INCY $12.23
- BAP $25.88
- Revenue Next Year
- INCY $8.89
- BAP $6.03
- P/E Ratio
- INCY $454.93
- BAP $9.84
- Revenue Growth
- INCY 14.76
- BAP 12.46
- 52 Week Low
- INCY $50.35
- BAP $153.27
- 52 Week High
- INCY $83.95
- BAP $200.00
- Technical
- Relative Strength Index (RSI)
- INCY 38.27
- BAP 44.76
- Support Level
- INCY $68.17
- BAP $178.67
- Resistance Level
- INCY $72.81
- BAP $185.73
- Average True Range (ATR)
- INCY 2.29
- BAP 4.45
- MACD
- INCY -0.32
- BAP -0.21
- Stochastic Oscillator
- INCY 8.61
- BAP 29.98
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About BAP Credicorp Ltd.
Credicorp Ltd is a Peruvian financial services company. It operates in four business lines including Universal Banking, Insurance and Pensions, Microfinance, and Investment Management & Advisory. Its subsidiaries include Banco de Credito del Peru, Prima AFP, and Credicorp Capital.